Pharvaris (NASDAQ:PHVS) Stock Price Down 6% Following Insider Selling

Pharvaris N.V. (NASDAQ:PHVS) traded down 6% on Friday following insider selling activity. The stock traded as low as $29.09 and last traded at $29.1550. 163,274 shares traded hands during trading, a decline of 14% from the average session volume of 190,164 shares. The stock had previously closed at $31.01.

Specifically, insider Peng Lu sold 3,733 shares of Pharvaris stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $30.06, for a total transaction of $112,213.98. Following the transaction, the insider owned 62,350 shares in the company, valued at approximately $1,874,241. The trade was a 5.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Peng Lu sold 15,000 shares of the company’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $30.24, for a total value of $453,600.00. Following the completion of the sale, the insider directly owned 66,083 shares of the company’s stock, valued at $1,998,349.92. The trade was a 18.50% decrease in their position. The disclosure for this sale is available in the SEC filing. In other news, insider Anne Lesage sold 3,700 shares of the stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $30.08, for a total value of $111,296.00. Following the completion of the sale, the insider owned 56,450 shares in the company, valued at approximately $1,698,016. This trade represents a 6.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on PHVS shares. Citigroup reiterated a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Wall Street Zen lowered Pharvaris from a “sell” rating to a “strong sell” rating in a research note on Monday, April 13th. Wolfe Research started coverage on Pharvaris in a research note on Thursday, April 9th. They issued an “outperform” rating and a $42.00 target price for the company. Royal Bank Of Canada lowered their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Finally, Wedbush increased their target price on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $42.73.

Key Headlines Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Insiders still retain large, meaningful stakes after the sales, which can indicate alignment with shareholders and limit the likelihood of continued big disposals. Examples: director Johannes Schikan remains a large shareholder (~355k shares after sales) and others still hold six‑figure stakes. SEC Filing
• Neutral Sentiment: Commentary noting that director sales may matter less than upcoming company catalysts — suggests investors should watch near‑term clinical/regulatory milestones rather than focus only on the trades. For Pharvaris Investors, the Director’s Sale Matters Less Than What’s Coming Next
• Negative Sentiment: Anne Lesage sold multiple blocks (3,700; 19,200; 21,700 shares) across April 29–30 at ≈$30.08–$30.26, reducing her position by as much as ~27.8% in filings and generating >$1.34M in proceeds — a signal that prompted selling pressure. SEC Filing
• Negative Sentiment: Peng Lu executed two sales (3,733 and 15,000 shares) on April 29–30 at ≈$30.06–$30.24, cutting ownership by up to ~18.5% and raising roughly $565.8k — another substantial insider liquidity event. SEC Filing
• Negative Sentiment: Director Johannes Gerardus Chri Schikan sold two blocks (3,830 and 29,070 shares) on April 29–30 at ≈$30.07–$30.32, a ~7.6% cut in his holdings and ~ $996.6k in disclosed proceeds — adding to the overall sell pressure. SEC Filing

Pharvaris Trading Down 5.1%

The business has a 50 day simple moving average of $27.62 and a two-hundred day simple moving average of $26.06. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of -8.74 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.15). Research analysts anticipate that Pharvaris N.V. will post -3.19 EPS for the current fiscal year.

Institutional Investors Weigh In On Pharvaris

A number of hedge funds have recently bought and sold shares of PHVS. Geode Capital Management LLC grew its stake in Pharvaris by 41.1% during the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after purchasing an additional 15,769 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. Legal & General Group Plc grew its stake in Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares in the last quarter. Amundi grew its stake in Pharvaris by 2,741,600.0% during the 2nd quarter. Amundi now owns 27,417 shares of the company’s stock valued at $489,000 after purchasing an additional 27,416 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in Pharvaris by 19.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock valued at $860,000 after purchasing an additional 7,879 shares in the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.